NanoRepro

NanoRepro Inventory

The Inventory of NanoRepro (NN6.DE) as of Oct 14, 2026 is 633,633.00 EUR. In the previous year, Inventory was 901,400.00 EUR — a change of -29.71% (lower).

Inventory

633,633.00EUR

YoY

-29.71%

Last updated:

Inventory of NanoRepro is 2025 633,633.00 EUR. Inventory of NanoRepro was 2024 901,400.00 EUR. It decreases by -29.71% lower compared to the previous year.

The NanoRepro Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
677,828.00 EUR
Jan 1, 2019
569,229.00 EUR
Jan 1, 2020
2.57 M EUR
Jan 1, 2021
17.95 M EUR
Jan 1, 2022
1.62 M EUR
Jan 1, 2023
603,934.00 EUR
Jan 1, 2024
901,400.00 EUR
Jan 1, 2025
633,633.00 EUR
The NanoRepro Inventory history
YEARInventoryYoY
633,633.00EUR-29.71%
901,400.00EUR+49.25%
603,934.00EUR-62.76%
1.62 MEUR-90.96%
17.95 MEUR+599.43%
2.57 MEUR+350.80%
569,229.00EUR-16.02%
677,828.00EUR-7.79%
735,078.00EUR+73.87%
422,779.00EUR+4.84%
403,259.00EUR-8.35%
440,000.00EUR—
Access this data via the Eulerpool API

NanoRepro Stock analysis

What does NanoRepro do? The Nanorepro AG was founded in 1998 in Marburg an der Lahn and has since developed into a leading company in the development and production of diagnostic rapid tests and self-tests. The company has been listed on the Frankfurt Stock Exchange since 2006 and has its headquarters in the university city of Marburg. Nanorepro's business model focuses on the production and distribution of innovative, reliable, and easy-to-use self-tests for the medical field. The company concentrates on the practical application of the tests - they should be simple, fast, and user-friendly. Nanorepro's core competence lies in the design, production, and distribution of rapid tests and self-tests for the medical field. The company relies on close cooperation with other companies and research institutions to continuously improve the tests and develop new products. Nanorepro focuses on various areas, including the manufacturing of rapid tests and self-tests for the diagnosis of infectious diseases. In addition, the company also offers tests to check pregnancy status or determine ovulation. Nanorepro's range of products also includes self-tests for the early detection of diseases such as diabetes. With its wide range of products, the company is able to address a large customer base and achieve a positive market position. One key product of Nanorepro is the early pregnancy test. This product is easy to handle and allows women to quickly and safely determine if they are pregnant or not. Nanorepro also offers an ovulation test to help women determine the timing of ovulation. Another test offered by the company is the Lyme borreliosis self-test, which allows for the detection of antibodies to Lyme borreliosis. Nanorepro also offers numerous tests for diagnosing infectious diseases. These include tests that can diagnose bacterial or viral infections such as streptococcal infections or hepatitis B and C. The tests are highly accurate and reliable, enabling quick diagnosis and treatment. Another area in which Nanorepro is expanding is the development of self-tests for the early detection of cancer. For this purpose, the company works closely with scientific and research institutions to continuously improve the tests and make them even more precise and reliable. Nanorepro places a strong emphasis on quality control and safety in the production of the tests. The products are CE-certified, ensuring high quality and safety for the user. In addition, the company has been certified according to the standards of the International Quality Management System ISO 13485, guaranteeing a high standard in the production and marketing of medical devices. Overall, Nanorepro AG has established itself as a leading company in the field of rapid tests and self-tests. With its wide range of products and constant willingness to innovate, the company is able to quickly and effectively respond to the requirements of customers and partners. The company's extensive experience in the field of medical diagnostics contributes to Nanorepro being perceived as a reliable partner in medical technology. NanoRepro is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NanoRepro stock

Inventory of NanoRepro is 633,633.00 EUR in 2025.

Inventory of NanoRepro changed from 901,400.00 EUR to 633,633.00 EUR, representing a -29.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory NanoRepro since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's NanoRepro historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — NanoRepro

All Key Metrics — NanoRepro